A Study to Assess the Efficacy and Safety of AKST4290 With Aflibercept in Patients With Newly Diagnosed nAMD

NCT04331730 · clinicaltrials.gov ↗

PHASE2

Phase

COMPLETED

Status

107

Enrollment

INDUSTRY

Sponsor class

Conditions

Neovascular Age-related Macular Degeneration

Interventions

DRUG: AKST4290
DRUG: Placebo
DRUG: Aflibercept

Sponsor

Alkahest, Inc.